-
KX2-391 Dihydrochloride: Applied Workflows
2026-09-17
KX2-391 dihydrochloride connects Src-substrate inhibition with tubulin disruption, enabling mechanism-aware oncology screens rather than single-endpoint cytotoxicity assays. The same reagent also supports distinct HBV transcription and BoNT/A workflows when concentration ranges, controls, and orthogonal readouts are kept separate.
-
Puromycin in AAV Translation and Selection Strategy
2026-09-17
Puromycin dihydrochloride is more than a routine selectable reagent: it is a translation-level perturbation that can strengthen how engineered AAV capsids are validated. This thought-leadership guide connects pac-based selection, ribosome biology, and the nanobody-directed AAV tropism study to help translational researchers separate vector entry, expression, and cellular fitness.
-
Cefotaxime as a Lens on Resistance Assays
2026-09-16
Cefotaxime can do more than inhibit bacterial growth: it can help researchers connect resistance genotype, mobile-element biology, and phenotype. This evidence-led guide shows how to use the third-generation cephalosporin antibiotic in antimicrobial resistance research without overinterpreting susceptibility data.
-
L. plantarum DS0037 ELNs: Senolytic and Senomorphic Effects
2026-09-16
This 2024 study identifies exosome-like nanovesicles from Lactobacillus plantarum DS0037 as a microbial-derived candidate with both senolytic and senomorphic activity. The vesicles preferentially reduced senescent-cell viability, moderated inflammatory and matrix-remodeling markers, and produced early improvements in skin-elasticity-related measures, although the evidence remains primarily preclinical and model-dependent.
-
Nirmatrelvir: A 3CLpro Assay Interpretation Guide
2026-09-15
Nirmatrelvir (PF-07321332) is examined through a decision-focused framework for linking 3CLpro inhibition to SARS-CoV-2 replication biology. This guide emphasizes assay interpretation, orthogonal controls, compound handling, and the practical limits of docking-based evidence.
-
Merbromin Inhibits SARS-CoV-2 3CLpro
2026-09-15
A high-throughput biochemical screen of approximately 6,000 compounds identified merbromin as a selective inhibitor of the SARS-CoV-2 3-chymotrypsin-like protease, 3CLpro. Kinetic, binding, and docking analyses supported a mixed-type mechanism involving two binding sites, providing a mechanistic starting point for antiviral inhibitor development.
-
ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors
2026-09-14
The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination experiments further show that RTK inhibition can increase temozolomide-associated toxicity, supporting ATRX status as a useful stratification variable in translational studies rather than as a standalone clinical biomarker.
-
2-Hydroxypropyl-β-cyclodextrin Workflow Guide
2026-09-14
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide used to screen inclusion complex formation and improve the aqueous handling of poorly soluble hydrophobic compounds, particularly those containing aromatic or phenyl groups. This dossier-based guidance supports pharmaceutical and biochemical workflows, but it does not establish compound-specific therapeutic efficacy, clinical bioavailability, or performance outside those applications.
-
ABT-888 (Veliparib) Workflow for DNA Damage Studies
2026-09-13
ABT-888 (Veliparib) offers a practical way to probe PARP1/2-dependent DNA repair inhibition and sensitize cancer models to chemotherapy or radiation. This workflow connects colorectal cancer research and MSI tumor models with replication-stress biology, including the biomarker insights of recent ovarian cancer research.
-
Clarithromycin as a CYP3A Inhibitor
2026-09-12
Clarithromycin is a macrolide antibiotic and CYP3A inhibitor used in drug-drug interaction research and pharmacokinetic studies. Its defined solvent profile, storage requirement, and CYP3A-centered mechanism support controlled enzyme and exposure experiments, but they do not replace clinical interaction assessment.
-
ER-Targeting Peptide Self-Assembly in Cancer
2026-09-11
This study develops an alkaline-phosphatase-instructed peptide that combines p-toluenesulfonamide-mediated endoplasmic reticulum targeting with enzyme-instructed self-assembly. The resulting assemblies selectively accumulate in ALP-rich cancer cells, induce ER stress and dysfunction, and promote apoptosis and necroptosis at lower effective concentrations than a non-targeted intracellular strategy.
-
Phylloquinone Protects Neurons from OGD Ferroptosis
2026-09-11
The reference study identifies phylloquinone as a neuroprotective compound that reduces oxygen-glucose deprivation-induced neuronal injury by suppressing ferroptosis through the xCT/GPX4 pathway. Its findings connect ferroptosis control with reduced oxidative damage and cellular senescence, while positioning Klf2 as a potential mechanistic mediator requiring further validation.
-
ABT-888 (Veliparib): PARP1/2 Research Guide
2026-09-10
ABT-888, also called Veliparib, is a selective PARP1/2 inhibitor used to study DNA repair inhibition and treatment sensitization. Its strongest dossier-supported applications are preclinical colorectal cancer research, combination chemotherapy, and radiation-response experiments rather than direct clinical treatment.
-
Caspase-4 Colorimetric Assay Kit for Pyroptosis
2026-09-10
Quantify LEVD-dependent caspase-4 activity with a practical colorimetric workflow suited to pyroptosis, inflammatory signaling, and exploratory cancer-cell fate studies. The assay adds an enzyme-activity endpoint that can be paired with GSDMD, IL-1β, viability, and ER-stress measurements rather than relying on morphology alone.
-
DiscoveryProbe Natural Product Library Plus
2026-09-09
A mechanism-first roadmap for using natural product screening for drug discovery against Cryptosporidium parvum AdhE, linking biochemical inhibition to cellular validation and translational decision-making.